Bioequivalence Study of Amoxicillin and Clavulanic Acid 875 mg/125 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions

The primary objective of this study is to evaluate the **bioequivalence** of Amoxicillin and Clavulanic Acid 875 mg/125 mg film-coated tablets in healthy participants under fed conditions. Bioequivalence studies are crucial in determining whether two pharmaceutical products are equivalent in terms of their bioavailability, which is essential for ensuring therapeutic equivalence and consistent clinical outcomes. This study does not involve any specific medical condition, as it is conducted in healthy participants to assess the pharmacokinetic properties of the drug formulation.

The clinical trial involves a study population that includes both **female** and **male** participants. The age range of the participants is categorized as "3," which typically corresponds to a specific age group, though the exact ages are not specified. The trial includes a **vulnerable population**, indicating that special considerations are taken into account for these participants. The sponsor has not provided information regarding the total number of participants involved in the study. The trial does not focus on any specific medical condition, as indicated by the absence of a defined medical condition for the study. The selection process for the trial population and any lifestyle considerations such as diet, physical activity, or habits have not been disclosed. Key inclusion or exclusion criteria are not specified, and the main objective of the trial is not provided.

The clinical trial is designed to evaluate the **bioequivalence** of Amoxicillin and Clavulanic Acid 875 mg/125 mg film-coated tablets in healthy participants under fed conditions. This study is a Phase 2 trial, which is categorized as a randomized, double-blind, controlled trial. The estimated recruitment start date is July 17, 2024, with an anticipated end date of September 5, 2024. The trial does not involve participants with any specific medical condition, as it is conducted in healthy individuals.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive the investigational product or a comparator under controlled conditions. The trial will include multiple follow-up visits to monitor safety, tolerability, and pharmacokinetic parameters. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to ensure participant safety and collect any remaining data.

The expected length of participant involvement is approximately two months, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified. Furthermore, there is no information on the product's authorization status or the origin of the active substances.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. Consequently, there is no information available on the administration, dosing schedules, or participant compliance monitoring for these treatments. The absence of this data limits the ability to describe the full scope of the clinical trial's treatment regimen.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to begin recruitment on July 17, 2024, with an estimated end date of September 5, 2024. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The methods and schedule for measuring, collecting, and analyzing these efficacy parameters are not specified. The trial will proceed according to the standard protocols for a Phase 2 study, focusing on the assessment of efficacy in the context of the investigational treatment. The trial's design and execution will adhere to regulatory and ethical standards to ensure the reliability and validity of the efficacy data collected.